Tirzepatide Dosage Chart: Complete Escalation Guide

Tirzepatide dosage escalation chart#

Tirzepatide (brand names: Mounjaro for type 2 diabetes, Zepbound for obesity) uses a mandatory dose escalation schedule to allow the body to adapt and minimise GI side effects. The approved escalation schedule is: Weeks 1–4: 2.5 mg once weekly (starting dose, not a therapeutic dose) Weeks 5–8: 5 mg once weekly Weeks 9–12: 7.5 mg once weekly (optional, can stay at 5 mg if tolerated) Weeks 13–16: 10 mg once weekly Weeks 17–20: 12.5 mg once weekly Weeks 21+: 15 mg once weekly (maximum approved dose) The 2.5 mg starting dose is a titration dose only — it produces minimal weight loss but is essential for tolerability. Many patients see significant weight loss beginning at the 5–10 mg range. Maintenance dose: Most patients find an effective maintenance dose between 5 mg and 15 mg. Not everyone needs to reach 15 mg. The goal is the lowest dose that achieves and maintains your target outcomes.

Tirzepatide is a prescription medication. This dosage information is educational. Always follow your prescribing physician's protocol.

Dose escalation: when to go up and when to pause#

The standard protocol advances one dose tier every 4 weeks. However, dose escalation should be paused if: GI side effects are severe: persistent nausea, vomiting, or diarrhoea that interferes with daily life or eating. Advancing while experiencing significant GI symptoms typically worsens them. Insufficient time at current dose: 4 weeks is the minimum — staying longer at a dose is fine. Some patients remain at 5 mg or 7.5 mg long-term if the results are satisfactory. Body weight plateau: A plateau after reaching a higher dose may suggest you're at your effective dose. Continuing to escalate beyond what's needed adds side effect risk without additional benefit for some individuals. Signs you're ready to advance: GI symptoms have largely resolved, you're comfortable with the injection routine, and weight loss has plateaued at the current dose. Many clinicians recommend staying at each dose for 6–8 weeks rather than the minimum 4 weeks if any GI symptoms are present. The body typically adapts within this window.

Compounded tirzepatide: dosing considerations#

Compounded tirzepatide refers to tirzepatide base or tirzepatide salts (typically tirzepatide hydrochloride or tirzepatide acetate) prepared by compounding pharmacies. It became widely available during the brand-name shortage period and continues to circulate as a lower-cost alternative. Key differences from brand-name Mounjaro/Zepbound: - Compounded preparations use vials rather than auto-injectors; patients draw and self-inject with insulin syringes - Some compounders use tirzepatide salts with different molecular weights — dose equivalence to the base form may differ - Manufacturing quality varies; compounders must be licensed (503A or 503B pharmacy) - The FDA has expressed concerns about compounded GLP-1s and their status changes — check current guidance Dosing compounded tirzepatide: Because compounded vials come in varying concentrations (e.g., 5 mg/mL, 10 mg/mL, or custom), confirm the concentration label before drawing. Calculate your volume: desired dose (mg) ÷ concentration (mg/mL) = volume to inject (mL). Convert to syringe units: volume (mL) × 100 = units on a U-100 insulin syringe. Example: 5 mg dose from a 10 mg/mL vial = 0.5 mL = 50 units on a U-100 syringe.

Managing side effects during escalation#

GI side effects (nausea, vomiting, diarrhoea, constipation) are the most common challenge during tirzepatide escalation. Evidence-based strategies: Injection timing: Injecting in the evening allows the peak GI effect to occur during sleep for many patients. Some prefer morning injections — experiment to find what minimises disruption. Food choices: Eat small, frequent, low-fat meals during the first 1–2 weeks after a dose increase. Avoid fatty, greasy, or spicy foods. High-fat meals significantly worsen nausea by further slowing gastric emptying. Hydration: Nausea can reduce fluid intake — prioritise water and electrolytes, particularly if experiencing vomiting or diarrhoea. Ginger: Ginger (tea, capsules, candied ginger) has modest evidence for nausea reduction and is commonly used by GLP-1 users. Anti-nausea medication: Ondansetron (Zofran) is sometimes prescribed by physicians for the first weeks of each dose escalation step. Ask your prescriber if GI symptoms are severe. Constipation: More common at higher doses. Prioritise dietary fibre, hydration, and consider a gentle osmotic laxative (polyethylene glycol) if needed. Stimulant laxatives are generally avoided during ongoing GLP-1 use.

If GI side effects are severe or persistent, pause escalation and discuss with your physician. Do not advance dose through significant side effects.

Tirzepatide vs semaglutide: which is right for you?#

Both tirzepatide and semaglutide are GLP-1 receptor agonists used for weight loss, but they differ in mechanism and efficacy. Semaglutide (Wegovy/Ozempic) acts solely on the GLP-1 receptor. The STEP trials showed 15–17% average body weight reduction over 68 weeks. It's available in brand-name auto-injector form and widely through compounding pharmacies. Tirzepatide (Zepbound/Mounjaro) is a dual agonist — it activates both GLP-1 and GIP receptors. The SURMOUNT trials showed 20–22% average body weight reduction. The additional GIP mechanism appears to improve tolerability (particularly nausea) while enhancing efficacy. For weight loss efficacy: Tirzepatide has demonstrated superior weight loss in head-to-head context. The SUPASS-J trial directly compared the two and confirmed greater weight reduction with tirzepatide. For access and cost: Compounded semaglutide remains the most widely available low-cost option. Brand-name tirzepatide was added to formularies more recently; compounded tirzepatide availability varies by region. For tolerability: Despite being more potent, tirzepatide's GIP component appears to counter some of the nausea associated with pure GLP-1 agonism, making it tolerable for many patients who had difficulty with semaglutide. For diabetes management: Both are approved for T2D. Tirzepatide has additional mechanistic advantages for insulin secretion via the GIP receptor.